Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Publication
, Journal Article
Jindal, T; Jiang, CY; Alhalabi, O; Nguyen, CB; Oh, E; Tsung, I; Bakaloudi, DR; Talukder, R; Davidsohn, M; Freeman, D; Epstein, IY; Ding, C-KC ...
Published in: Eur Urol
September 14, 2025
Duke Scholars
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
September 14, 2025
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jindal, T., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Oh, E., Tsung, I., … Koshkin, V. S. (2025). Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol. https://doi.org/10.1016/j.eururo.2025.09.003
Jindal, Tanya, Cindy Y. Jiang, Omar Alhalabi, Charles B. Nguyen, Eugene Oh, Irene Tsung, Dimitra Rafailia Bakaloudi, et al. “Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.” Eur Urol, September 14, 2025. https://doi.org/10.1016/j.eururo.2025.09.003.
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, et al. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol. 2025 Sep 14;
Jindal, Tanya, et al. “Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.” Eur Urol, Sept. 2025. Pubmed, doi:10.1016/j.eururo.2025.09.003.
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding C-KC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol. 2025 Sep 14;
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
September 14, 2025
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences